The European Medicines Agency has begun a review of its operations and processes, focused on increasing the efficiency of its scientific activities and information- and communication-technology operations. As part of this process, it will focus on the support provided to the Agency’s scientific committees to help them deliver high-quality, consistent opinions.
The Agency expects this process to result in a significant reorganisation of its staff during 2013.
This process will involve significant effort from scientific and support staff across the Agency over the next few months, and will have an impact on the ability of the Agency to contribute to external meetings and forums, probably until spring 2013. In most instances, the Agency will cancel attendance by its staff, although participation by video- or teleconference may be a feasible alternative.
Announcing the decision, the Agency’s Executive Director Guido Rasi said, “the aim of this exercise is to improve our processes and how best to use our resources, not least to ensure that we are better prepared for future legislative and policy challenges. I apologise in advance to event organisers for any disappointment this may cause in the months ahead.”
Please direct any specific enquires to: [email protected]